SEARCH
MENU
The items were successfully added to the cart.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. Find out more
DISEASE

DISEASE

MODEL

MODEL

PHASE

PHASE

Choose your prefered product category above

OCT 16TH, 2018

Life Cycle Management – part three: Assay development

In the third part of the Life Cycle Management video series, Hanna Ritzén, Managing Director of R&D guides us through the important steps of assay development.

SEP 19TH, 2018

Relationship between oxLDL and the early stage of atherosclerosis

A recent study in the Journal of Atherosclerosis and Thrombosis reveals that serum levels of oxidized low-density lipoprotein (oxLDL) can predict 10-year progression of sub-clinical atherosclerosis, and that this is independent of the cholesterol content, the number and size of LDL particles.

SEP 24TH, 2018

Anneli Palm new chairman of the board

Mercodia announced today the appointment of Anneli Palm as the new chairman of the board. Anneli Palm has been a member of the board since 2009 and replaces her father, Erling Holmlund as chairman.

Latest Tweet
Mercodia @Mercodia Oct 17th, 2018
We know you have been waiting for it! Part 3 of #LCMbyMercodia is here now! Don´t miss this opportunity to learn ab… https://t.co/IA9MPQRQBg

NOV 16TH, 2017

How to choose your glucagon assay

How does one choose which glucagon assay to use? What is important to think about regarding sensitivity, matrix interference and cross-reactivity?

GLP-1 WHITE PAPER - IMPORTANT ASPECTS TO CONSIDER WHEN MEASURING GLP-1

Find answers to these questions: 

  • Why measure total GLP-1?
  • Why is amidated GLP-1 so important?
  • What is the expected level of GLP-1 in different patient samples?
  • How is GLP-1 targeted in treatment strategies?

Altered Levels of Glucagon and Glicentin in Adolescents With Obesity and Type 2 Diabetes

The prevalence of childhood obesity has increased worldwide in the past decades, which has been accompanied by a rise in obesity-related comorbidities such as type 2 diabetes mellitus (T2DM). 

Mercodia Bioanalytical Service

Mercodia's Bioanalytical Service provides you with the experience, quality and reliability that are fundamental to a productive partnership. Our experienced team of managers, scientists, technicians and regulatory resources will support you in everything from study design to sample handling. We follow the most recent international guidelines and industry standard white papers for bioanalytical method development and validation.

Our combined expertise will ensure that your studies of PK, PD and biomarkers are performed with the highest possible measurement quality, enabling you to make informed decisions based on accurate bioanalytical data. We are highly flexible in the transfer of data in different formats, to meet individual sponsor needs. 

 

WHITE PAPER on GLUCAGON MEASUREMENT Addressing Long-Standing Analytical Challenges

 

 LOOK INSIDE FOR ANSWERS TO THESE QUESTIONS: 

  • What technical aspects of commercial glucagon assays have prevented them from meeting scientists’ needs? 
  • Are there analytical solutions available to meet those needs?

 

Podcasts

Exploring Frontiers in Translational Research
Learn about scientific advances that lead to a better understanding of diseases and therapies. Interviews with scientists and clinicians will provide you with cutting-edge information, coming directly from the source.  Explore topics ranging from drug discovery and new FDA regulations to novel approaches to metabolic diseases (e.g., diabetes and heart disease).
 

Support

At Mercodia, we pride ourselves on providing our customers with quick, accurate support. Below you will find answers to some common questions. If you do not find what you are looking for, please feel free to contact us: contacts

Contact

Our professional and experienced Customer Service and Technical Support teams are dedicated to ensuring complete customer satisfaction.